Jagiellonian University Medical College, Department of Drug Management, Faculty of Health Sciences , Grzegórzecka 20, PL 31-531 Kraków , Poland
Expert Opin Investig Drugs. 2015 Apr;24(4):585-94. doi: 10.1517/13543784.2014.979283. Epub 2014 Oct 31.
Social anxiety disorder (SAD) is one of the most common psychiatric disorders, causing a reduction of in the quality of life by impairing functioning in social situations. The lifetime prevalence of SAD is estimated to be 12%. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are considered first-line drugs for SAD. However, new effective therapeutic options are still needed. Pregabalin is a novel anxiolytic, which seems to be a promising therapy for SAD.
This review presents the results of three randomized controlled trials (RCTs) comparing the efficacy and safety of pregabalin with placebo in patients with generalized SAD. The authors also discuss the long-term safety and tolerability data from an extension study.
The results of the RCTs have demonstrated efficacy and safety with pregabalin at doses of 600 mg or 450 mg/d for treating generalized SAD. Thus, pregabalin may be an effective therapeutic option, especially for patients who cannot tolerate the adverse effects or who demonstrate a lack of efficacy with SSRIs or SNRIs. In addition to being an alternative therapy to SSRIs or SNRIs, it may also have value as an add-on therapy, either to augment pharmacotherapy or in addition to cognitive-behavioral therapy.
社交焦虑障碍（SAD）是最常见的精神障碍之一，它会损害社交场合的功能，从而降低生活质量。SAD 的终生患病率估计为 12%。选择性 5-羟色胺再摄取抑制剂（SSRIs）和 5-羟色胺-去甲肾上腺素再摄取抑制剂（SNRIs）被认为是 SAD 的一线药物。然而，仍需要新的有效治疗选择。普瑞巴林是一种新型的抗焦虑药，似乎是治疗 SAD 的一种有前途的疗法。
本文综述了三项比较普瑞巴林与安慰剂治疗广泛性 SAD 患者疗效和安全性的随机对照试验（RCT）的结果。作者还讨论了一项扩展研究的长期安全性和耐受性数据。
RCT 的结果表明，普瑞巴林的疗效和安全性与其剂量有关，600mg 或 450mg/d 的剂量可用于治疗广泛性 SAD。因此，普瑞巴林可能是一种有效的治疗选择，特别是对于不能耐受不良反应或对 SSRIs 或 SNRIs 反应不佳的患者。除了作为 SSRIs 或 SNRIs 的替代疗法之外，它还可能具有附加治疗的价值，无论是增强药物治疗还是与认知行为疗法联合使用。
